SINGAPORE (May 24): QT Vascular has entered into an asset purchase and option agreement to sell its non-drug coated coronary product line and related intellectual property (IP) licenses to Teleflex Life Sciences Unlimited Company and Teleflex Incorporated in a deal worth up to $32.8 million.

On top of the purchase price of $26.2 million, QT Vascular will receive two separate payments of $3.3 million each when Teleflex achieves certain milestones set for the worldwide annual net revenue from the sales of the non-coated coronary products.

The agreement also provides NYSE-listed Teleflex with an option to purchase the drug coated coronary balloon catheter known as Chocolate Heart, which is currently under development by QT Vascular.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook